ArticleTherapeutic advances in neurological disorders2011
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.
Article in Therapeutic advances in neurological disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 93 citations in OpenAlex.
- Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label study.Journal of clinical pharmacology · 2014Trial
- A review of multiple sclerosis: From pathophysiology to latest therapeutic advances.AIMS neuroscience · 2025Review
- Review
- Rehabilitation therapy versus drug-only therapy in patients with multiple sclerosis.Turkish journal of medical sciences · 2024Observational
- Can spa rehabilitative interventions play a role for patients suffering from neurodegenerative disorders at the early stages? A scoping review.International journal of biometeorology · 2022Article
- Neurorehabilitation in Multiple Sclerosis-A Review of Present Approaches and Future Considerations.Journal of clinical medicine · 2022Review
- Seizures and multiple sclerosis‑more than an epidemiological association (Review).Experimental and therapeutic medicine · 2022Review
- Ontology for Symptomatic Treatment of Multiple Sclerosis.Healthcare informatics research · 2022Article
- Integrated Approaches to Identify miRNA Biomarkers Associated with Cognitive Dysfunction in Multiple Sclerosis Using Text Mining, Gene Expression, Pathways, and GWAS.Diagnostics (Basel, Switzerland) · 2022Article
- In Vivo Assessment of the Ameliorative Impact of Some Medicinal Plant Extracts on Lipopolysaccharide-Induced Multiple Sclerosis in Wistar Rats.Molecules (Basel, Switzerland) · 2022Article
- Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration.Current neuropharmacology · 2022Review
- The Wahls Behavior Change Model for Complex Chronic Diseases: A Clinician's Guide.Degenerative neurological and neuromuscular disease · 2022Article
- How Multiple Sclerosis Symptoms Vary by Age, Sex, and Race/Ethnicity.Neurology. Clinical practice · 2021Article
- Perspectives on urological care in multiple sclerosis patients.Intractable & rare diseases research · 2021Review
- Molecular Examination of Differentially Expressed Genes in the Brains of Experimental Autoimmune Encephalomyelitis Mice Post Herceptin Treatment.Journal of inflammation research · 2021Article
- Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.Neurology international · 2020Review
- Molecular Interventions towards Multiple Sclerosis Treatment.Brain sciences · 2020Review
- Inner Retinal Layer Disease: Multiple Sclerosis.Beyoglu eye journal · 2020Article
- Cognitive Dysfunctions and Assessments in Multiple Sclerosis.Frontiers in neurology · 2019Review
- Reliability and validity of the Eating Assessment Tool-10 (Greek adaptation) in neurogenic and head and neck cancer-related oropharyngeal dysphagia.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 12 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As more investigations into factors affecting the quality of life of patients with multiple sclerosis (MS) are undertaken, it is becoming increasingly apparent that certain comorbidities and associated symptoms commonly found in these patients differ in incidence, pathophysiology and other factors compared with the general population. Many of these MS-related symptoms are frequently ignored in assessments of disease status and are often not considered to be associated with the disease. Research into how such comorbidities and symptoms can be diagnosed and treated within the MS population is lacking. This information gap adds further complexity to disease management and represents an unmet need in MS, particularly as early recognition and treatment of these conditions can improve patient outcomes. In this manuscript, we sought to review the literature on the comorbidities and symptoms of MS and to summarize the evidence for treatments that have been or may be used to alleviate them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.